⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 1, 2024Journal of Gastrointestinal OncologyOpen Access

Efficacy and safety of camrelizumab combined with chemotherapy in the first-line treatment of advanced gastric cancer: a single-arm, phase II study

Wenlou Liu Hongmei Wang Yang Zhao Yan Ge Juangjuang Tang Menghan Cao Silvio Matsas Daniel Breadner Xiaobing Qin Zhengxiang Han

View Full Paper

Ask AI

Bookmark

Share

Abstract

Chemotherapy with SOX (S-1 and oxaliplatin) regimen showed good efficacy and a favorable safety profile in advanced gastric cancer. Anti-programmed cell death protein 1 (PD-1) antibody camrelizumab also demonstrated antitumor activity in this setting in a phase I study. However, the efficacy and safety of camrelizumab plus SOX for advanced gastric cancer have not been investigated. Thus, this study aimed to address this objective.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Liu et al. (2024) studied this question.

synapsesocial.com/papers/68e5dfdcb6db643587574795 https://doi.org/10.21037/jgo-24-336

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study2024 · 44 citations
2An exploratory clinical study of β-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma2024 · 10 citations
3A single-arm exploratory clinical study of β-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma.2024 · 1 citations
4PD-1 Inhibition With Camrelizumab in Cervical CancerMeta-Analysis · 2026
5Efficacy and safety of programmed death-1 inhibitors combined with chemotherapy in patients with advanced gastric cancer2025 · 1 citations